Statement: The same number of cases of Neutropenia, Febrile neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 18/115 (15.65%)   Febrile neutropenia * 7/115 (6.09%)   Neutropenia * 1/115 (0.87%)   Pancytopenia * 1/115 (0.87%)   Diarrhoea * 0/115 (0.00%)   Nausea * 0/115 (0.00%)   Stomatitis * 0/115 (0.00%)   Vomiting * 1/115 (0.87%)   Asthenia * 1/115 (0.87%)   Mucosal inflammation * 0/115 (0.00%)   Pyrexia * 3/115 (2.61%)   Gastrointestinal infection * 1/115 (0.87%) Adverse Events 2:   Total: 8/112 (7.14%)   Febrile neutropenia * 3/112 (2.68%)   Neutropenia * 2/112 (1.79%)   Pancytopenia * 0/112 (0.00%)   Diarrhoea * 2/112 (1.79%)   Nausea * 2/112 (1.79%)   Stomatitis * 1/112 (0.89%)   Vomiting * 1/112 (0.89%)   Asthenia * 0/112 (0.00%)   Mucosal inflammation * 1/112 (0.89%)   Pyrexia * 0/112 (0.00%)   Gastrointestinal infection * 0/112 (0.00%)